Loading clinical trials...
Loading clinical trials...
This is an open-study with a 26 week open label treatment period followed by an optional 26 week open label extension. The total treatment period will be 52 weeks.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
AbbVie
NCT07546435 · Psychological Experience in Fertility Treatment, Hypogonadism, and more
NCT06019182 · Intellectual Disability, Epilepsy, and more
NCT06689085 · Hypogonadism, Male
NCT07412782 · Osteogenesis Imperfecta, Osteoporosis, and more
NCT06583408 · Hypothalamic Amenorrhea, Functional, Hypothalamic Amenorrhea, and more
Site Reference ID/Investigator# 124163
Birmingham, Alabama
Site Reference ID/Investigator# 123938
Huntsville, Alabama
Site Reference ID/Investigator# 125782
Mesa, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions